Surgery Partners, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Surgery Partners reported Q2 2026 revenue of $848.9M (+2.7% YoY) with same-facility growth of 5.0%. However, net loss attributable to the company was $15.0M, and Adjusted EBITDA fell to $125.2M from $129.0M YoY. The company reaffirmed full-year 2026 guidance: revenue $3.35–3.45B and Adjusted EBITDA of $530M+. A pending divestiture of Idaho Falls facilities (to Intermountain Health) is expected to improve financial profile by reducing low-margin lines (Medicaid mix dropping from ~4% to <2%, eliminating obstetrics/neonatology, reducing ICU beds 50%) and high capex. Deal subject to physician, regulatory, and governing board approvals.
Why this rating
Pending divestiture (~$765M annualized revenue, ~$116M EBITDA—14.8% of full-year guidance, ~4.5% of total company value) is material but noncore; improves margins by cutting unprofitable lines. Q2 same-facility growth 5% is solid. YoY Adjusted EBITDA decline (-3%) and increased net loss (-500%) offset by reaffirmed guidance and strategic focus. Moderate execution risk on deal closing; modest near-term operational momentum.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.